Article

Martin Edelman, MD, Talks About Improving Outcomes in the Management of NSCLC

Conference|NAMCP: National Association of Managed Care Physicians Forum

Martin Edelman, MD, Greenbaum Cancer Center, Baltimore, MD, says that organizations like NCCN and ASCO have guidelines for the management of non-small cell lung cancer (NSCLC).

Martin Edelman, MD, Greenbaum Cancer Center, Baltimore, MD, says that organizations like NCCN and ASCO have guidelines for the management of non-small cell lung cancer (NSCLC). "I think that by utilizing these various clinical as well as biological markers, we can develop therapies that are tailored to the individual patient and have substantial evidence to support their use," said Dr Edelman.

This video was taken on May 2, 2013, at the NAMCP Spring Managed Care Forum in Orlando, FL.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Carrie Kitko
Dr Carrie Kitko
Dr Ibrahim Aldoss
Dr Pankit Vachhani
Dr Ibrahim Aldoss
Dr Pankit Vachhani
Dr John Mascarenhas
CK Wang, MD, COTA
Dr Pankit Vachhani
Dr John Mascarenhas
Related Content
The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com
July 9th 2025

Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

Jared Kaltwasser
Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than patients with cachexia.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Alexander I. Spira, MD, PhD | Image: Virginia Cancer Specialists
July 3rd 2025

COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus Lazertinib

Alexander I. Spira, MD, PhD Interview by Mary Caffrey
Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic treatment reduces dermatological adverse events in patients with non–small cell lung cancer (NSCLC), enhancing their quality of life during amivantamab therapy.
Managed Care Cast logo
April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski
June 29th 2025

Decline in SCLC Incidence Expected to Accelerate Through 2050

Jared Kaltwasser
The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.
While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
June 27th 2025

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

Kimberly Rath, PharmD
Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving immunotherapy, according to new research.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo